Abstract:OBJECTIVE: The expression of S100A6 (calcyclin), a member of the S100 calcium binding protein family, is elevated in a number of malignant tumors, but there have been few reports about its expression in gastric cancer. The aim of this study was to investigate its expression regulations in human gastric cancer and noncancerous mucosa, and the response to chemotherapeutic drugs in the gastric cancer cell line.MATERIALS AND METHODS: In one matched gastric cancer sample pair, the serial analysis of gene expression (SAGE) experiment was conducted to compare the gene expression profiles between cancerous and adjacent tissues. To detect the expression regulations among more cancerous tissues, microarrays were carried out and real-time RT-PCR was conducted to validate the results. At the protein level, Western blot and tissue microarray (TMA) examination were further used to verify S100A6 expression. The regulation. detection of S100A6 with flurouracil and doxorubicin at the mRNA and protein level was performed in the SGC7901 cell line.RESULTS: With the SAGE strategy, five times more S100A6 tags were identified in cancer tissues than in normal tissues. With the cDNA microarray, S100A6 was found to be significantly upregulated in 21 of 42 (50%) nonselective gastric cancers. In 10 other paired samples, the upregulation of S 100A6 was consolidated with RT-PCR and Western blot analysis as well. A total of 14 endoscopy-sectioned gastric noncancerous lesions and corresponding normal gastric mucosa were also applied to profile the gene expression; both cDNA microarray and RT-PCR demonstrated no significant alterations of S 100A6 at the mRNA level. TMA examination showed that 34 of 52 (65.4%) cancer samples were positively stained, while only 17 of 80 (21.3%) noncancerous lesions were positively detected and all nine normal mucosae were detected to be negative. An in vitro experiment showed that in the gastric cell line SGC-7901, S100A6 mRNA was detected to be upregulated from 24 to 72 h after treatment with 5 mg/L 5-flurouracil or 0.3 mg/L doxorubicin, and there were two wave upregulations of the S100A6 protein.CONCLUSION: The observed regulated expression of S100A6 suggests that it is associated with gastric cancer tumorigenesis and quantitation of S100A6 is a promising tool for diagnosis of gastric cancer.

The Role of S100A6 in Human Diseases: Molecular Mechanisms and Therapeutic Potential

S100A6: molecular function and biomarker role

Calcium-binding Protein S100P and Cancer: Mechanisms and Clinical Relevance

The Calcium Binding Protein S100A11 and Its Roles in Diseases

Analysis and prediction of structure and function of the related tumor protein S100A6

S100A8 and S100A9 in Cancer

Progress of Ca2+-binding protein S100A12

Research Progress on Relation Between EF-hand Calcium-Binding Protein S100A6 and Tumor

The S100 protein family in lung cancer

S100A6 represses Calu‐6 lung cancer cells growth via inhibiting cell proliferation, migration, invasion and enhancing apoptosis

S100A7:Biological properties and implications in diseases

The functions and regulatory pathways of S100A8/A9 and its receptors in cancers

S100A11: Diverse Function and Pathology Corresponding to Different Target Proteins

[Regulation Mechanism Study of S100A6 on Invasion and Metastasis in Gastric Cancer].

Roles of S100A8, S100A9 and S100A12 in infection, inflammation and immunity

Upregulated Expression Of S100a6 In Human Gastric Cancer

S100A6 and Its Brain Ligands in Neurodegenerative Disorders

Clinical Significance of S100A6 Protein Expression in Human Lung Adenocarcinoma

Selective Expression of Calcium-Binding Protein S100A7 in Lung Cancer

Increased Expression of S100A6 Promotes Cell Proliferation and Migration in Human Hepatocellular Carcinoma

The Role of the S100 Protein Family in Glioma